Author

Emily S. Meymand

University of California, BerkeleyORCID 0000-0002-7450-1380Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Alyssa J. Mathiowetz· 1 shared Ana Paula ArrudaiD· 1 shared Bin ZhangiD· 1 shared Brian W. ParksiD· 1 shared Casadora C. A. Boone· 1 shared Cheryl E. G. LeynsiD· 1 shared Cody E. DoubravskyiD· 1 shared Connor M. WebbiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

Alyssa J. Mathiowetz

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CLCC1 promotes hepatic neutral lipid flux and nuclear pore complex assembly

Alyssa J. Mathiowetz, Emily S. Meymand, Güneş Parlakgül, Niek van Hilten, Emily F. Torres, Leonardo Luís Artico, Kirandeep K. Deol, Mike Lange, Stephany P. Pang, Cody E. Doubravsky, Melissa A. Roberts, Danielle M. Jorgens, Reena Zalpuri, Misun Kang, Casadora C. A. Boone, , James A. Olzmann

This study identifies CLCC1 as a regulator of hepatic neutral lipid flux and nuclear pore complex assembly through CRISPR screens and functional analyses.

Nature · Feb 25, 2026Peer-reviewedCell Biology

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread

Noah Lubben, Julia K. Brynildsen, Connor M. Webb, Howard Liu Li, Cheryl E. G. Leyns, Lakshmi N. Changolkar, Bin Zhang, Emily S. Meymand, Mia O’Reilly, Zach B. Madaj, Daniella DeWeerd, Matthew J. Fell, Virginia M.‐Y. Lee, Danielle S. Bassett, Michael X. Henderson

This study shows that LRRK2 kinase inhibition reverses tau pathology progression in mice with the G2019S mutation but not in wildtype mice.

Translational Neurodegeneration · Mar 4, 2024Peer-reviewedNeuroscience